导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.51% | 1868/4773 |
| 近一周 | -2.50% | 2378/5462 |
| 近一月 | -2.82% | 1418/5421 |
| 近一季 | -5.47% | 1853/5209 |
| 近半年 | -10.04% | 3589/4920 |
| 近一年 | 8.24% | 1210/4366 |
| 近两年 | 60.42% | 1203/2954 |
| 近三年 | 38.14% | 771/2253 |
| 成立以来 | 156.47% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
4.56% 501/4961 |
1.27% 3053/5312 |
- - |
- - |
| 2025 | 27.79% 1536/4813 |
0.84% 1755/3635 |
1.78% 2153/4076 |
20.92% 1899/4524 |
2.97% 797/4813 |
| 2024 | 12.61% 1227/3463 |
3.39% 580/2808 |
-0.46% 767/3014 |
9.65% 2681/3129 |
-0.22% 1349/3463 |
| 2023 | -8.26% 994/2656 |
6.20% 712/2280 |
-4.74% 1273/2385 |
-3.98% 1032/2515 |
-5.56% 1396/2655 |
| 2022 | -20.90% 1000/2207 |
-10.18% 380/1919 |
2.11% 1353/2016 |
-10.52% 418/2113 |
-3.61% 1858/2208 |
| 2021 | 10.51% 431/1822 |
-5.49% 929/1255 |
8.06% 649/1330 |
6.56% 218/1466 |
1.55% 881/1822 |
| 2020 | 31.20% 505/1250 |
-1.82% 242/1028 |
18.45% 335/1067 |
10.26% 568/1164 |
2.33% 998/1184 |
| 2019 | 24.79% 611/1092 |
24.26% 519/754 |
-7.57% 563/804 |
1.83% 352/850 |
6.70% 569/918 |
| 2018 | -28.24% 438/834 |
- - |
- - |
- - |
-12.17% 417/691 |
| 2017 | -5.03% 507/714 |
- - |
- - |
- - |
- - |
| 2016 | -18.59% 423/605 |
- - |
- - |
- - |
- - |
| 2015 | 43.89% 37/575 |
- - |
- - |
- - |
- - |
| 2014 | 36.40% 141/237 |
- - |
- - |
- - |
- - |
| 2013 | 13.23% 35/186 |
- - |
- - |
- - |
- - |
| 2012 | -2.04% 131/140 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 中邮中证500指数增强A VS. 长安沪深300非周期A(740101) |